A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Placebo of CDP870

Given every 2 weeks until Week22 (SC)

DRUG

CDP870 200mg

400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week 22(SC)

DRUG

Methotrexate

"Received treatment with Methotrexate(MTX)for at least 24 weeks prior to the Baseline Visit.~The dose and route of administration of MTX had to have been stable for at least 8 weeks prior to the Baseline Visit. The minimum stable dose of MTX allowed is 10mg weekly."

Trial Locations (15)

700-721

Kyungpook National University Hospital, Daegu

Unknown

Catholic University Hospital of Daegu, Daegu

Inha University Hospital, Inchon

Chonnam National University Hospital, Kwangju

Pusan National University Hospital, Pusan

Gangnam Severance Hospital, Seoul

Hanyang Universoty Hospital, Seoul

KonKuk University Medical Center, Seoul

Seoul national univeristy, Seoul

Ajou University Hospital, Suwon

302-799

Eulji University Hospital, Daejeon

120-752

Yonsei University Severance Hospital, Seoul

135-710

Samsung Medical Center, Seoul

138-736

Asan Medical Center, Seoul

150-713

Catholic University of Korea ST.Mary's Hospital, Seoul

All Listed Sponsors
lead

Korea Otsuka Pharmaceutical Co., Ltd.

INDUSTRY